aminocaproic acid has been researched along with Adverse Drug Event in 4 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "epsilon-Aminocaproic acid (EACA) is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage." | 3.74 | Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. ( Chwajol, M; Connolly, ES; Ducruet, AF; Fernandez, A; Hahn, DK; Hickman, ZL; Kellner, CP; Kim, GH; Komotar, RJ; Mayer, SA; Otten, ML; Starke, RM, 2008) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Starke, RM | 1 |
| Kim, GH | 1 |
| Fernandez, A | 1 |
| Komotar, RJ | 1 |
| Hickman, ZL | 1 |
| Otten, ML | 1 |
| Ducruet, AF | 1 |
| Kellner, CP | 1 |
| Hahn, DK | 1 |
| Chwajol, M | 1 |
| Mayer, SA | 1 |
| Connolly, ES | 1 |
| Henry, D | 1 |
| Carless, P | 1 |
| Fergusson, D | 1 |
| Laupacis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
1 review available for aminocaproic acid and Adverse Drug Event
| Article | Year |
|---|---|
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery | 2009 |
3 other studies available for aminocaproic acid and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Clinical Protocols; Drug Adm | 2008 |